We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Novel Digital Pathology Approach Helps Identify New NSCLC Biomarkers

By LabMedica International staff writers
Posted on 21 Jun 2023
Print article
Image: Researchers have identified new biomarkers of the most frequent lung cancer (Photo courtesy of Freepik)
Image: Researchers have identified new biomarkers of the most frequent lung cancer (Photo courtesy of Freepik)

Lung cancer is the leading cause of cancer-related deaths among both genders globally, with a five-year survival rate standing at a mere 18%. Non-small cell lung cancer (NSCLC), divided further into adenocarcinoma, squamous cell carcinoma, and a few rarer types, is the most common diagnosis for these patients. Emerging evidence underscores the critical role of the collagen fiber-rich microenvironment surrounding cancer cells in the growth of these cancers and other solid tumors. In this tumor context, high type I collagen expression is linked to poor prognosis and higher metastasis risk. This association suggests that fibrillar collagens could serve as a key source of cancer-relevant biomarkers and has sparked interest in deciphering their roles in tumor development.

In response to this challenge, researchers at the University of Barcelona (Barcelona, Spain) and the Institute of Bioengineering of Catalonia (IBEC, (Barcelona, Spain) have developed and validated a novel digital pathology approach that quantitatively analyzes collagen fibers in tissue samples from NSCLC patients. The approach utilizes digitized images of patient biopsies stained with a dye named picrosirius red (PSR) and imaged with polarized light. The researchers employed the open-source software CT-FIRE to automatically segment individual fibers in the images and quantify critical characteristics like length, width, or straightness.

The team applied this methodology to analyze 195 samples from patients with adenocarcinoma and squamous cell carcinoma. The findings suggest that fiber straightness could serve as a potential disease biomarker, while high density could indicate a poor prognosis. Interestingly, the prognostic relevance of collagen density appears independent of the clinical tumor stage, suggesting that collagen fiber analysis provides additional crucial information. The new methodology also enabled the comparison of collagen fibers in patient tissue samples with non-cancerous tissue samples. This allowed, for the first time, a quantitative description of the changes occurring in collagen organization in NSCLC. The findings indicate that tumor tissue samples showed an increase in straightness, length, and width, suggestive of abnormal tissue stiffening, especially in adenocarcinoma patients. According to the researchers, this stiffening could be related to various mechanisms that help the tumor evade the immune response, thereby potentially facilitating tumor progression in this type of cancer.

“Our new tool can improve the clinical management of surgical patients with this type of cancer, since it identifies those at an increased risk of relapse and, therefore, can benefit from a comprehensive monitoring and even neoadjuvant therapies (complementary to the main treatment)”, noted Jordi Alcaraz, lecturer at the Faculty of Medicine and Health Sciences of the UB and researcher at IBEC.

Related Links:
University of Barcelona 
IBEC 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.